KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
press release announcing its financial results for the three
months ended March 31, 2017 and recent business developments. A
copy of the press release is attached to this Current Report on
Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
accompanying Exhibit 99.1, shall not be deemed to be filed for
the purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act), or otherwise subject to the liability of such
section, nor shall such information be deemed to be incorporated
by reference in any subsequent filing by the Company under the
Securities Act of 1933 or the Exchange Act, regardless of the
general incorporation language of such filing, except as
specifically stated in such filing.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release of Kindred Biosciences, Inc. issued on
May 3, 2017. |
About KINDRED BIOSCIENCES, INC. (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis. KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Recent Trading Information
KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) closed its last trading session up +0.30 at 6.95 with 50,837 shares trading hands.
